½ÃÀ庸°í¼­
»óǰÄÚµå
1600437

¾ç¸· ½ÃÀå : Á¦Ç°, ¿ëµµ, ÃÖÁ¾»ç¿ëÀÚº° - ¼¼°è ¿¹Ãø(2025-2030³â)

Amniotic Membrane Market by Product (Cryopreserved Amniotic Membrane, Lyophilization Amniotic Membrane), Application (Ophthalmology, Surgical Wound), End User - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 193 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

¾ç¸· ½ÃÀåÀº 2023³â¿¡ 10¾ï 2,000¸¸ ´Þ·¯·Î Æò°¡µÇ¸ç, 2024³â¿¡´Â 11¾ï 3,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, CAGR 9.26%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 19¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¾ç¸· ½ÃÀåÀº ÀÓ»êºÎÀÇ ÅÂ¹Ý Á¶Á÷¿¡¼­ ÃßÃâÇÑ »ýü Á¶Á÷ ¿¬±¸ ¹× °ø±Þ°ú °ü·ÃÀÌ ÀÖ½À´Ï´Ù. Ç׿°Áõ, Ç×¼¶À¯È­, Ç×±Õ¼ºÀ¸·Î À¯¸íÇÏ¸ç »óó Ä¡À¯, ¾È°ú, Àç°Ç ¼ö¼ú¿¡ µµ¿òÀÌ µË´Ï´Ù. ¾ç¸· ½ÃÀåÀÇ ¹üÀ§´Â ÀÇ·á¿ë, Ư¼ö¿ë, ¾È°ú¿ëÀ¸·Î ´Ù¾çÇÏ¸ç º´¿ø, Ŭ¸®´Ð, ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC), Àü¹® Ä¡·á ¼¾ÅÍ¿Í °°Àº ÃÖÁ¾»ç¿ëÀÚ¿¡°Ô ¼­ºñ½º¸¦ Á¦°øÇÕ´Ï´Ù. ÀÌ ½ÃÀåÀÇ Áß¿äÇÑ ¼ºÀå ¿äÀÎÀº °í±ÞÀÇ È¿°úÀûÀÎ Ä¡·á ¿É¼ÇÀ» ÇÊ¿ä·Î ÇÏ´Â ¸¸¼ºÁúȯ°ú ºÎ»óÀÇ À¯º´·ü Áõ°¡¿Í ÃÖ¼Òħ½À ¼ö¼ú¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡ÀÔ´Ï´Ù. ÀÇ·á ±â¼úÀÇ ¹ßÀüµµ ½ÃÀåÀ» °­È­ÇÏ¿© Á¦Ç°ÀÇ È¿´ÉÀ» Çâ»ó½ÃŰ°í »õ·Î¿î ¿ëµµÀÇ ÀáÀç·ÂÀ» Á¦°øÇÕ´Ï´Ù. ÁÖ¿ä ºñÁî´Ï½º ±âȸ´Â Àç»ýÀÇ·á ºÐ¾ßÀÇ ¿ëµµ È®´ë¿Í »õ·Î¿î Àü´Þ ¹æ½Ä¿¡ ´ëÇÑ Å½»ö¿¡ ÀÖ½À´Ï´Ù. ±×·¯³ª ÀÌ ½ÃÀåÀº ¾ö°ÝÇÑ ±ÔÁ¦ ¿ä°Ç°ú Á¶Á÷ äÃë ¹× Á¦Á¶¸¦ µÑ·¯½Ñ ÀáÀçÀû À±¸® ¹®Á¦¿Í °°Àº Á¦¾à¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¾ç¸· Á¦Ç°Àº »ó´ëÀûÀ¸·Î °í°¡À̱⠶§¹®¿¡ ƯÈ÷ ºñ¿ë¿¡ ¹Î°¨ÇÑ ½ÃÀå¿¡¼­´Â º¸±Þ¿¡ °É¸²µ¹ÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. ÇコÄÉ¾î ºÐ¾ßÀÇ ±ÔÁ¦°¡ °­È­µÊ¿¡ µû¶ó ±â¾÷Àº Á¦Ç°ÀÇ ºñ¿ë È¿À²¼º °³¼±, »ýü ÀûÇÕ¼º Çâ»ó, ¸âºê·¹ÀÎ º¸Á¸ ¹× Àû¿ë ¹æ¹ýÀÇ ¹ßÀü°ú °°Àº ºÐ¾ß¿¡¼­ Çõ½ÅÀ» ¸ð»öÇÒ ¼ö ÀÖ½À´Ï´Ù. ÇÕ¼º ¶Ç´Â »ý¸í°øÇÐ ´ëüǰ¿¡ ´ëÇÑ ¿¬±¸´Â »õ·Î¿î ¼ºÀåÀÇ ±æÀ» ¿­¾îÁÙ ¼ö ÀÖ½À´Ï´Ù. ½ÃÀå ¿ªÇÐÀº °æÀï ±¸µµ¸¦ º¸¿© ÁÖ¸ç, ±â¾÷Àº Çõ½Å°ú Â÷º°È­¸¦ ¿ä±¸Çϰí ÀÖ½À´Ï´Ù. ½ÃÀåÀÇ Æ¯¼ºÀº ÁÖ·Î ±Þ¼ÓÇÑ ±â¼ú ¹ßÀü°ú ¸ÂÃãÇü ÀÇ·á·ÎÀÇ Áö¼ÓÀûÀÎ Àüȯ¿¡ ¿µÇâÀ» ¹Þ°í ÀÖ½À´Ï´Ù. ¼ºÀå ±âȸ¸¦ È¿°úÀûÀ¸·Î Ȱ¿ëÇϱâ À§ÇØ ½ÃÀå ÁøÃâ±â¾÷Àº Àü·«Àû Á¦ÈÞ¸¦ ¿ì¼±½ÃÇϰí, R&D ÅõÀÚ¸¦ °­È­Çϰí, ±ÔÁ¦ »óȲ¿¡ ´ëÇÑ ³ë·ÂÀ» ±â¿ïÀ̰í, ½ÂÀÎ ÀýÂ÷¸¦ °£¼ÒÈ­ÇÏ¿© ½ÃÀå ħÅõ¸¦ °­È­Çϰí, ÁøÈ­ÇÏ´Â ÀÇ·á ȯ°æ¿¡¼­ ´õ °­·ÂÇÑ ÀÔÁö¸¦ ±¸ÃàÇØ¾ß ÇÕ´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁسâ[2023] 10¾ï 2,000¸¸ ´Þ·¯
¿¹Ãø³â[2024] 11¾ï 3,000¸¸ ´Þ·¯
¿¹Ãø³â[2030] 19¾ï ´Þ·¯
CAGR(%) 9.26%

½ÃÀå ¿ªÇÐ: ºü¸£°Ô ÁøÈ­ÇÏ´Â ¾ç¸· ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

¾ç¸· ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ëÀ» ÅëÇØ º¯È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ ÁøÈ­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº Á¤º¸¿¡ ÀÔ°¢ÇÑ ÅõÀÚ °áÁ¤, Àü·«Àû ÀÇ»ç°áÁ¤, »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Æ÷ÂøÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µ¿ÇâÀ» Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¿ªÀû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ ¿ÏÈ­Çϰí, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¹× ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ¾ç¸· ÀÌ½Ä ¼ö¿ä
    • ¼¼°è ³ëÀÎ Àα¸ Áõ°¡
    • »ç°í ¹× ¿Ü»ó ¹ß»ý·ü Áõ°¡
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ÇコÄÉ¾î ºÐ¾ßÀÇ ¼÷·ÃµÈ Àü¹® Àη ºÎÁ·
  • ½ÃÀå ±âȸ
    • ¾ç¸·ÀÇ Àç»ýÀÇ·á ¹× Áٱ⼼Æ÷ »ý¹°ÇÐ ¿¬±¸°³¹ß Ȱµ¿ Áõ°¡
    • ¾ç¸·ÀÇ ÀåÁ¡°ú Ãâ»ý½Ã Á¶Á÷ ±âÁõ¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡
  • ½ÃÀå °úÁ¦
    • ÃæºÐÇÑ º¸°ü ¿Âµµ ¼öÁØ À¯Áö

Portre's Five Forces: ¾ç¸· ½ÃÀå Ž»öÀ» À§ÇÑ Àü·« Åø

Portre's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ ÅøÀÔ´Ï´Ù. Portre's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ Ž»öÇÒ ¼ö ÀÖ´Â ¸íÈ®ÇÑ ¹æ¹ýÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÀλçÀÌÆ®À» ÅëÇØ ±â¾÷Àº °­Á¡À» Ȱ¿ëÇϰí, ¾àÁ¡À» ÇØ°áÇϰí, ÀáÀçÀûÀÎ µµÀüÀ» ÇÇÇϰí, º¸´Ù °­·ÂÇÑ ½ÃÀå Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : ¾ç¸· ½ÃÀå¿¡¼­ÀÇ ¿ÜºÎ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº ¾ç¸· ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀο¡ ´ëÇÑ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇϸç, PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀû À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£µµ, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¼±Á¦ÀûÀÌ°í ´Éµ¿ÀûÀÎ ÀÇ»ç°áÁ¤À» ³»¸± Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® ¾ç¸· ½ÃÀå¿¡¼­ °æÀï ±¸µµ ÆÄ¾Ç

¾ç¸· ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¸ÅÃâ, °í°´ ±â¹Ý, ¼ºÀå·ü°ú °°Àº ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀïÀû À§Ä¡¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®Àº ½ÃÀåÀÇ ÁýÁßÈ­, ´ÜÆíÈ­, ÅëÇÕÀÇ Ãß¼¼¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖÀ¸¸ç, °ø±Þ¾÷ü´Â Ä¡¿­ÇÑ °æÀï ¼Ó¿¡¼­ ÀÚ½ÅÀÇ ÀÔÁö¸¦ °­È­ÇÒ ¼ö ÀÖ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ ÀλçÀÌÆ®À» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º ¾ç¸· ½ÃÀå¿¡¼­°ø±Þ¾÷ü ¼º°ú Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â ¾ç¸· ½ÃÀå¿¡¼­ °ø±Þ¾÷ü¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ ÅøÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº º¥´õÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±â¹ÝÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ºÎÇÕÇÏ´Â Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖÀ¸¸ç, 4°³ÀÇ »çºÐ¸éÀº º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ±¸ºÐÇÏ¿© »ç¿ëÀÚ°¡ Àü·«Àû¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù. ½Äº°ÇÒ ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â Á¾ÇÕÀûÀÎ ½ÃÀå ºÐ¼®À» Á¦°øÇÕ´Ï´Ù. :

1. ½ÃÀå ħÅõµµ : ¾÷°è ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅ͸¦ Æ÷ÇÔÇÑ ÇöÀç ½ÃÀå ȯ°æ¿¡ ´ëÇÑ »ó¼¼ÇÑ °ËÅä.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇϰí, ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡Çϸç, ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù°¢È­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä ¹ßÀü, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú ¹ßÀü µîÀ» °ËÅäÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÷´Ü ±â¼ú, ¿¬±¸°³¹ß Ȱµ¿ ¹× Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

ÀÌÇØ°ü°èÀÚµéÀÌ ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï ´ÙÀ½°ú °°Àº Áß¿äÇÑ Áú¹®¿¡ ´ëÇÑ ´äº¯µµ Á¦°øÇÕ´Ï´Ù. :

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå Àü¸ÁÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹®, Áö¿ªÀº?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5.º¥´õ ½ÃÀå ÁøÀÔ ¹× ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÔ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå °³¿ä

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±âȸ
    • °úÁ¦
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ¹ý·ü
    • ȯ°æ

Á¦6Àå ¾ç¸· ½ÃÀå : Á¦Ç°º°

  • ³Ãµ¿ º¸Á¸µÈ ¾ç¸·
  • µ¿°á°ÇÁ¶ ¾ç¸·

Á¦7Àå ¾ç¸· ½ÃÀå : ¿ëµµº°

  • ¾È°ú
  • ¼ö¼úâ

Á¦8Àå ¾ç¸· ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

  • ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ
  • º´¿ø
  • ¿¬±¸ ¼¾ÅÍ ¿¬±¸¼Ò
  • Àü¹® Ŭ¸®´Ð

Á¦9Àå ¾Æ¸Þ¸®Ä«ÀÇ ¾ç¸· ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦10Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¾ç¸· ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦11Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ¾ç¸· ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®
  • ¿µ±¹

Á¦12Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼® 2023
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®

±â¾÷ ¸®½ºÆ®

  • VIVEX Biologics, Inc.
  • Stryker Corporation
  • Smith & Nephew PLC
  • Celularity Inc.
  • Lucina BioSciences, LLC
  • Thea Pharma Inc.
  • Merakris Therapeutics
  • Ventris Medical, LLC
  • NuVision Biotherapies Ltd
  • FzioMed Inc.
  • Laboratoire CCD
  • Surgenex, LLC
  • Surgilogix
  • BioTissue Holdings, Inc.
  • Integra LifeSciences Holdings Corporation
  • Katena Products, Inc.
  • Genesis Biologics Inc.
  • PuraGraft
  • Seed Biotech, Inc.
  • The Electrospinning Company
  • MiMedx Group, Inc.
  • Applied Biologics, LLC
  • Skye Biologics Holdings, LLC
  • BioStem Technologies, Inc.
  • Organogenesis Holdings Inc.
  • Next Biosciences(Pty) Limited
KSA 24.12.05

The Amniotic Membrane Market was valued at USD 1.02 billion in 2023, expected to reach USD 1.13 billion in 2024, and is projected to grow at a CAGR of 9.26%, to USD 1.90 billion by 2030.

The amniotic membrane market involves the study and supply of a biological tissue derived from the placental tissue of pregnant women. It is renowned for its anti-inflammatory, anti-fibrotic, and anti-microbial properties, making it instrumental in wound healing, ophthalmology, and reconstructive surgeries. The scope of the amniotic membrane market extends across medical, specialty, and ophthalmic applications, serving an array of end-users including hospitals, clinics, ambulatory surgical centers, and specialized treatment centers. A significant growth driver for this market is the rising prevalence of chronic diseases and injuries that necessitate advanced and effective treatment options, paired with the growing demand for minimally invasive surgeries. Advances in medical technology also bolster the market, offering potential for enhanced product effectiveness and new application areas. Key opportunities lie in expanding applications within regenerative medicine and exploring novel delivery formats. However, the market faces limitations such as stringent regulatory requirements and potential ethical issues surrounding tissue harvesting and manufacturing. Additionally, the relatively high cost of amniotic membrane products can deter widespread adoption, especially in cost-sensitive markets. As regulations in the healthcare sector become more stringent, companies can find innovation in areas such as improving cost-effectiveness of products, enhancing bio-compatibility, and advancing the methods of membrane preservation and application. Research into synthetic or bioengineered alternatives may present new growth avenues. Market dynamics indicate a competitive landscape, with firms pressured to innovate and differentiate. The market's nature is primarily influenced by rapid technological advancements and an ongoing shift towards personalized medicine. To effectively capitalize on growth opportunities, market players should prioritize strategic collaborations, pursue rigorous R&D investments, and engage in regulatory advocacy to streamline approval processes, thereby enhancing market penetration and establishing a stronger presence in the evolving medical landscape.

KEY MARKET STATISTICS
Base Year [2023] USD 1.02 billion
Estimated Year [2024] USD 1.13 billion
Forecast Year [2030] USD 1.90 billion
CAGR (%) 9.26%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Amniotic Membrane Market

The Amniotic Membrane Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Demand for amniotic membrane transplantations
    • Rising the geriatric population around the world
    • Growing incidence of accident and trauma cases
  • Market Restraints
    • Lack of skilled professionals in healthcare sector
  • Market Opportunities
    • Increasing R&D activities in the amniotic membrane for regenerative medicine and stem cell biology
    • Growing awareness of amniotic membrane benefits and birth tissue donations
  • Market Challenges
    • Maintaining sufficient storage temperature level

Porter's Five Forces: A Strategic Tool for Navigating the Amniotic Membrane Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Amniotic Membrane Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Amniotic Membrane Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Amniotic Membrane Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Amniotic Membrane Market

A detailed market share analysis in the Amniotic Membrane Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Amniotic Membrane Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Amniotic Membrane Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Amniotic Membrane Market, highlighting leading vendors and their innovative profiles. These include VIVEX Biologics, Inc., Stryker Corporation, Smith & Nephew PLC, Celularity Inc., Lucina BioSciences, LLC, Thea Pharma Inc., Merakris Therapeutics, Ventris Medical, LLC, NuVision Biotherapies Ltd, FzioMed Inc., Laboratoire CCD, Surgenex, LLC, Surgilogix, BioTissue Holdings, Inc., Integra LifeSciences Holdings Corporation, Katena Products, Inc., Genesis Biologics Inc., PuraGraft, Seed Biotech, Inc., The Electrospinning Company, MiMedx Group, Inc., Applied Biologics, LLC, Skye Biologics Holdings, LLC, BioStem Technologies, Inc., Organogenesis Holdings Inc., and Next Biosciences (Pty) Limited.

Market Segmentation & Coverage

This research report categorizes the Amniotic Membrane Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Cryopreserved Amniotic Membrane and Lyophilization Amniotic Membrane.
  • Based on Application, market is studied across Ophthalmology and Surgical Wound.
  • Based on End User, market is studied across Ambulatory Surgical Center, Hospital, Research Centers Laboratory, and Specialized Clinic.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Demand for amniotic membrane transplantations
      • 5.1.1.2. Rising the geriatric population around the world
      • 5.1.1.3. Growing incidence of accident and trauma cases
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of skilled professionals in healthcare sector
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing R&D activities in the amniotic membrane for regenerative medicine and stem cell biology
      • 5.1.3.2. Growing awareness of amniotic membrane benefits and birth tissue donations
    • 5.1.4. Challenges
      • 5.1.4.1. Maintaining sufficient storage temperature level
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Increase in use of cryopreserved amniotic membranes live cell therapy
    • 5.2.2. Application: Employment of amniotic membrane in ophthalmology treating complex ocular surface diseases
    • 5.2.3. End User: Significant use products across Hospitals for surgical procedures
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental
  • 5.5. Client Customization

6. Amniotic Membrane Market, by Product

  • 6.1. Introduction
  • 6.2. Cryopreserved Amniotic Membrane
  • 6.3. Lyophilization Amniotic Membrane

7. Amniotic Membrane Market, by Application

  • 7.1. Introduction
  • 7.2. Ophthalmology
  • 7.3. Surgical Wound

8. Amniotic Membrane Market, by End User

  • 8.1. Introduction
  • 8.2. Ambulatory Surgical Center
  • 8.3. Hospital
  • 8.4. Research Centers Laboratory
  • 8.5. Specialized Clinic

9. Americas Amniotic Membrane Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Amniotic Membrane Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Amniotic Membrane Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. NovaBay to commercialize Amniotic Tissue Allograft as Avenova Allograft
    • 12.3.2. Coloplast announces agreement to acquire Kerecis and raises long-term growth expectations

Companies Mentioned

  • 1. VIVEX Biologics, Inc.
  • 2. Stryker Corporation
  • 3. Smith & Nephew PLC
  • 4. Celularity Inc.
  • 5. Lucina BioSciences, LLC
  • 6. Thea Pharma Inc.
  • 7. Merakris Therapeutics
  • 8. Ventris Medical, LLC
  • 9. NuVision Biotherapies Ltd
  • 10. FzioMed Inc.
  • 11. Laboratoire CCD
  • 12. Surgenex, LLC
  • 13. Surgilogix
  • 14. BioTissue Holdings, Inc.
  • 15. Integra LifeSciences Holdings Corporation
  • 16. Katena Products, Inc.
  • 17. Genesis Biologics Inc.
  • 18. PuraGraft
  • 19. Seed Biotech, Inc.
  • 20. The Electrospinning Company
  • 21. MiMedx Group, Inc.
  • 22. Applied Biologics, LLC
  • 23. Skye Biologics Holdings, LLC
  • 24. BioStem Technologies, Inc.
  • 25. Organogenesis Holdings Inc.
  • 26. Next Biosciences (Pty) Limited
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦